Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 20, 2007
Last updated: August 23, 2013
Last verified: March 2008

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with trastuzumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving trastuzumab after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether trastuzumab is more effective than observation when given after combination chemotherapy and trastuzumab in treating patients with breast cancer.

PURPOSE: This randomized phase II trial is studying trastuzumab to see how well it works compared with observation when given after combination chemotherapy and trastuzumab in treating patients undergoing surgery for stage II or stage III breast cancer.

Condition Intervention Phase
Breast Cancer
Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: fluorouracil
Drug: paclitaxel
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated With Neoadjuvant Trastuzumab

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Percentage of pathological responses
  • Disease-free survival

Secondary Outcome Measures:
  • Overall survival at 3 years
  • Cardiac toxicity
  • Percentage of patients that become negative on the fluorescence in situ hybridization (FISH) test at the end of neoadjuvant therapy

Estimated Enrollment: 160
Study Start Date: September 2006
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed invasive breast cancer by needle biopsy

    • Diagnosed within the past 4 weeks
    • Clinical stage IIB, IIIA, IIIB, or IIIC disease
  • Palpable adenopathies present
  • HER2/neu-positive disease, as evidenced by either of the following:

    • HER2/neu overexpression (3+) by immunohistochemistry (IHC)
    • HER2/neu amplification by fluorescence in situ hybridization (FISH)
  • No metastatic disease by chest radiography, hepatic ultrasound, and bone scan (metastatic bone series if no nuclear medicine is available)
  • Hormone receptor status:

    • Estrogen receptor and/or progesterone receptor status known


  • Premenopausal or postmenopausal
  • WHO performance status 0-2
  • Not pregnant or nursing
  • Normal hepatic, renal, and hematological function
  • LVEF ≥ 55% by nuclear medicine study or echocardiogram
  • No prior history of cancer, except carcinoma in situ of the cervix
  • No allergic reaction or hypersensitivity to paclitaxel and/or trastuzumab (Herceptin®)


  • No prior cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00533936

Instituto Nacional de Cancerologia Recruiting
Mexico City, Distrito Federal, Mexico, 14000
Contact: Claudia Arce-Salinas, MD    52-55-5628-0400      
Hospital General de Mexico Recruiting
Mexico City, Distrito Federal, Mexico, C.P. 06726
Contact: Contact Person    52-55-5999-6133      
Sponsors and Collaborators
Instituto Nacional de Cancerologia, Columbia
Principal Investigator: Claudia Arce-Salinas, MD Instituto Nacional de Cancerologia, Columbia
  More Information Identifier: NCT00533936     History of Changes
Other Study ID Numbers: CDR0000557417
Study First Received: September 20, 2007
Last Updated: August 23, 2013

Keywords provided by National Cancer Institute (NCI):
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antimetabolites, Antineoplastic processed this record on April 21, 2017